US Stock Market Move | Hims&Hers Health (HIM.US) continues to rise by more than 15%, surging 72% in the past three trading days.

On Wednesday, Hims & Hers Health (HIM.US) continued to rise by over 15% in early trading, with a staggering 72% surge over the past three trading days, now trading at $27. In terms of news, Novo Nordisk A/S Sponsored ADR Class B and Hims & Hers will collaborate to sell obesity drugs. Novo Nordisk A/S Sponsored ADR Class B has agreed to sell its flagship drugs Ozempic and Wegovy on the Hims platform, including the popular Wegovy oral tablet. Citigroup Inc. has given high praise to this collaboration in its latest research report, seeing it as a significant turning point in Hims & Hers Health's development history. Additionally, as Hims & Hers Health prepares to enter a new phase of selling branded weight loss drugs, the company has hired Kathryn Beiser, who was Head of Corporate Communications at pharmaceutical giant Eli Lilly (LLY.US) for five years. CEO Andrew Dudum stated in a statement, "At this crucial moment, she is the communications leader we need."